Ergocalciferol clinical uses
Pro Research Analysisby 
Searched over 200M research papers
Ergocalciferol Clinical Uses in Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism
Ergocalciferol (vitamin D2) is widely used to treat vitamin D deficiency, especially in patients with chronic kidney disease (CKD). In CKD, ergocalciferol and its analogs, such as doxercalciferol, are effective in managing secondary hyperparathyroidism (SHPT) by reducing parathyroid hormone (PTH) levels and improving bone pathology. Doxercalciferol, a synthetic analog, is particularly useful because it is activated in the liver and does not require kidney function for activation, making it suitable for CKD patients across all stages. Its efficacy is comparable to other vitamin D analogs, and it may cause less hypercalcemia than some alternatives, making it a safe option for SHPT management in CKD Park2014Zhang2016.
Ergocalciferol for Endothelial and Microcirculatory Function
Ergocalciferol supplementation has shown benefits beyond bone health in CKD patients. It improves microcirculatory endothelial function, likely by increasing the expression and activity of endothelial nitric oxide synthase. This effect is independent of changes in bone mineral parameters, blood pressure, or left ventricular mass, suggesting a direct vascular benefit. Preclinical studies also show that ergocalciferol enhances both vasodilatory and vasoconstrictor responses in models of mild uraemia, further supporting its role in improving vascular health in CKD Dreyer2014Dreyer2019.
Ergocalciferol in Hemodialysis and Mineral Bone Disorder
In patients on hemodialysis with vitamin D deficiency, ergocalciferol supplementation effectively raises serum 25(OH)D levels. However, it does not significantly impact erythropoiesis (as measured by epoetin use), PTH, calcium, phosphorus, or clinical outcomes over six months. Similarly, in CKD stages 3–5, ergocalciferol is as effective and safe as calcitriol for managing mineral and bone disorders, with both treatments maintaining target levels of calcium, phosphorus, and PTH Miskulin2016Zhang2016.
Ergocalciferol for Vitamin D Deficiency in Special Populations
Epileptic Children and Adolescents
Children with epilepsy are at increased risk for vitamin D deficiency, especially when taking antiepileptic drugs. High-dose ergocalciferol (60,000 IU every 10 days for 90 days) is more effective than standard dosing in normalizing serum 25(OH)D levels, with no reported adverse events. However, children with higher BMI may require additional monitoring, as they are at greater risk for persistent deficiency .
Bariatric Surgery Patients
Vitamin D insufficiency is common after bariatric surgery. Monthly high-dose ergocalciferol (100,000 IU) is a safe and effective way to improve vitamin D status in these patients, with a greater increase in serum 25(OH)D compared to standard supplementation .
New-Onset Type 1 Diabetes
In youth with newly diagnosed type 1 diabetes, ergocalciferol supplementation reduces inflammatory markers (such as TNF-α) and slows the rise in HbA1c and insulin dose-adjusted A1c, suggesting a protective effect on residual β-cell function and partial clinical remission .
Ergocalciferol Versus Cholecalciferol (Vitamin D3)
While ergocalciferol is effective for raising vitamin D levels, systematic reviews and experimental studies indicate that cholecalciferol (vitamin D3) is generally more effective at increasing serum 25(OH)D and reducing PTH levels, regardless of dosage or patient demographics. The difference in efficacy is smaller at lower doses, but cholecalciferol remains the preferred option for most patients when available Chabas2013Balachandar2021.
Conclusion
Ergocalciferol is clinically useful for treating vitamin D deficiency and related complications in CKD, SHPT, epilepsy, bariatric surgery, and new-onset type 1 diabetes. It is effective and safe for improving vitamin D status and has additional benefits for vascular health in CKD. However, cholecalciferol may be more effective for raising vitamin D levels overall. Ergocalciferol remains a valuable option, especially when cholecalciferol is not available or in specific clinical scenarios.
Sources and full results
Most relevant research papers on this topic
Cholecalciferol (Vitamin D3) Improves Myelination and Recovery after Nerve Injury
Cholecalciferol (vitamin D3) is more efficient than ergocalciferol in promoting nerve regeneration and recovery after injury, with potential for future clinical trials in peripheral nerve or spinal cord repair.
Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial.
Ergocalciferol supplementation increased serum 25(OH)D levels in hemodialysis patients with vitamin D deficiency, but did not affect epoetin utilization or secondary biochemical and clinical outcomes.
Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: A randomized controlled trial.
Ergocalciferol has a similar long-term efficacy and safety profile as calcitriol for treating chronic kidney disease-mineral and bone disorders in stage 3 to 5 patients.
Standard and high dose ergocalciferol regimens for treatment of hypovitaminosis D in epileptic children and adolescents
Oral ergocalciferol 60,000 IU/10d for 90 days is more effective at normalizing serum 25-OHD than 20,000 IU/10d in epileptic children and adolescents receiving antiepileptic drugs.
Ergocalciferol in New-onset Type 1 Diabetes: A Randomized Controlled Trial
Ergocalciferol supplementation significantly reduces serum TNF- concentration and the rate of increase in A1c and IDAA1c, suggesting protection of residual -cell function and partial clinical remission in youth with newly diagnosed type 1 diabetes.
Relative Efficacy of Vitamin D2 and Vitamin D3 in Improving Vitamin D Status: Systematic Review and Meta-Analysis
Cholecalciferol is more effective than ergocalciferol in improving vitamin D status and regulating PTH levels, regardless of participant demographics, dosage, and supplementation vehicle.
Improving vitamin D status in bariatric surgery subjects with monthly high-dose ergocalciferol.
100,000 IUs of ergocalciferol once a month is a safe and effective treatment for vitamin D insufficiency in most patients after bariatric surgery.
DOI